Abstract:Today sclerotherapy is the elective treatment for most cases of telangiectases. The main exceptions are "red" telangiectases, those with a caliber <0.3 mm and those with high flow, which do not respond to sclerotherapy or are aggravated by it as they require high concentrations of locally and generally toxic sclerosant solutions. The aim of the study was to remove all types of telangiectases, reduce doses and concentrations of sclerosant drugs, reduce risks and side effects, improve course and recovery time an… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.